Asthma Subgroups: Treatment Options For Neutrophilic Asthma
This article represents the opinions, thoughts, and experiences of the author; none of this content has been paid for by any advertiser. The Asthma.net team does not recommend or endorse any products or treatments discussed herein. Learn more about how we maintain editorial integrity here.
- Wenzel, Sally, “Asthma phenotypes: the evolution from clinical to molecular approaches,” Nature Medicine, 2012, May, Vol. 18, No. 5, pages 716-725, http://www.healthylungs.com.au/resources/WenzelAstham-Phenotypes.pdf, accessed 10/31/16
- Wong, Ernie H.C., “The role of macrolides in severe asthma: current evidence and future directions,” Lancet, June, 2014, volume 2, no. 8, pages 657-670, . http://www.thelancet.com/journals/lanres/article/PIIS2213-2600(14)70107-9/abstract?rss=yes, accessed 12/31/16
- Brusselle, G.G., et al.,“Is there a role for macrolides in severe asthma?” ,Curr Opin Pulm Med. 2014 Jan;20(1):95-102, https://www.ncbi.nlm.nih.gov/pubmed/24247040, accessed 12/301/ 16 “
- “Formoteral attenuates neutrophilic airway inflammation in asthma,”Chest, 2005, https://www.ncbi.nlm.nih.gov/pubmed/16236838, accessed 12/29/16
- Tintinger, Gregory R., “Formoterol is more effective than salmeterol in suppressing neutrophil activity,” 2015, http://openres.ersjournals.com/content/1/1/00014-2015, European Respiratory Journal, accessed 12/29/16
- Katial, Rohit, editor, “Severe Asthma, An Issue of Immunology and Allergy Clinics of North America,” 2016, Elsevier, page 573-4
- "What is a biologic product?" FDA, http://www.fda.gov/AboutFDA/Transparency/Basics/ucm194516.htm, accessed 12/30/16
- Darveaux, Jared, et al., “Biologics in asthma -- the next step towards personalized treatments,” J Allergy Clin Immunol Pract. 2015 Mar-Apr; 3(2): 152–161.